Quark Pharmaceuticals
Quark Pharmaceuticals is a private, clinical-stage biopharmaceutical company founded in 1994 and based in Fremont, California, developing novel RNAi-based therapeutics built on siRNA gene-silencing technology, with no disclosed commercial products in the available data.
- Company typePrivate
- Founded1994
- HeadquartersFremont, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Quark Pharmaceuticals does
Quark Pharmaceuticals is a private, clinical-stage pharmaceutical company headquartered in Fremont, California, founded in 1994 and operating with an estimated 51–100 employees. The company is engaged in the discovery and development of novel RNAi-based therapeutics, with a stated core technology of siRNA (small interfering RNA) gene silencing.
The company has historically pursued capital through a series of equity funding rounds between 2001 and 2010, raising an identified cumulative total of approximately $61 million from investors including SBI Asset Management and Tako Ventures. There is no public documentation of commercialized products, named clinical partners, licensing deals, or regulatory milestones beyond what is implicit in a clinical-stage RNAi platform company. Leadership consists of founder and chair-CEO Daniel Zurr, CSO Elena Feinstein, COO Rami Skaliter, and President of US Operations / CMO Shai Erlich.
The available data does not include revenue, pricing, customer segments, product pipeline details, intellectual property portfolio, or post-2010 operating activity. The company's public website (quarkpharma.com) currently displays a cPanel default error page rather than active content, and no current operating status is independently verifiable from the source materials.
Quark Pharmaceuticals firmographics
Firmographics- Name
- Quark Pharmaceuticals
- Website
- https://quarkpharma.com
- Company type
- Private
- Founded year
- 1994
- Headcount range
- 51–100 employees
- Short description
- Quark Pharmaceuticals is a private, clinical-stage biopharmaceutical company founded in 1994 and based in Fremont, California, developing novel RNAi-based therapeutics built on siRNA gene-silencing technology, with no disclosed commercial products in the available data.
- Ownership category
- akta.pro rank
Quark Pharmaceuticals industry classification
Industry- Product category
- RNAi-based Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- siRNA Therapeutics (gene silencing) (HLAAADAB)
- akta.pro secondary industries
- RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
Keywords
Where Quark Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Markets served
Quark Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Quark Pharmaceuticals product offering
Product offeringCore offering
Quark Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of novel RNAi-based therapeutics. The company applies siRNA (small interfering RNA) gene silencing technology to develop innovative drug candidates targeting serious disease indications. As a clinical-stage company, its focus is on advancing therapeutic candidates through preclinical and clinical development rather than commercial product sales.
Differentiator
Problem solved
Functional benefit
Companies that use Quark Pharmaceuticals
Customer profileIdeal customer profiles2 records
Quark Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Quark Pharmaceuticals partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
Quark Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Alnylam Pharmaceuticals: Alnylam is the leading commercial-stage siRNA therapeutics company (Onpattro, Givlaari, Oxlumo, Amvuttra). It is the reference incumbent in Quark's exact modality and target indications (genetic disease gene silencing) and the dominant benchmark for any siRNA clinical asset value.
- Ionis Pharmaceuticals: Ionis is a leading RNA-targeted therapeutics company with multiple approved antisense drugs (Spinraza, Tegsedi, Waylivra) and broad partnerships. It operates in the adjacent RNA therapeutics space that overlaps with siRNA gene silencing and is a frequent counterpart in licensing deals.
- Arcturus Therapeutics: Arcturus is a clinical-stage RNA therapeutics company developing mRNA, siRNA, and related platforms including a partnered COVID vaccine. Its broader RNA platform approach and clinical-stage status make it a relevant adjacent peer for RNA modality comparison.
Direct peers
- Arrowhead Pharmaceuticals: Arrowhead is a clinical-stage siRNA therapeutics company with a broad pipeline and proprietary delivery technology (TRiM). It competes head-to-head for the same RNAi partnerships and licensing deals that Quark would pursue, making it the most direct comparable peer.
- Silence Therapeutics: Silence Therapeutics is a clinical-stage siRNA company (mRNA and gene silencing) with its own GalNAc delivery platform and a notable partnership with AstraZeneca. It is a direct peer in modality, stage, and go-to-market via big-pharma licensing.
- Wave Life Sciences: Wave is an oligonucleotide therapeutics company focused on gene silencing using stereopure chemistries (PRISM platform), directly comparable to Quark's siRNA chemistry focus and clinical-stage positioning.
- Dicerna Pharmaceuticals: Dicerna was a clinical-stage siRNA company (GalXC platform) acquired by Novo Nordisk in 2021 for $3.3B. Its pre-acquisition trajectory (clinical-stage RNAi, partnership-driven, similar headcount to Quark at acquisition) makes it the most relevant precedent transaction comp.
- Sirnaomics: Sirnaomics is a clinical-stage RNAi therapeutics company with both siRNA and mRNA programs, including oncology and anti-fibrotic indications. It is comparable in modality, clinical stage, and platform breadth to Quark's stated focus.
- Sylentis (Pharma Mar): Sylentis is a clinical-stage siRNA therapeutics subsidiary of Pharma Mar focused on ophthalmology and other indications. It is comparable as a niche clinical-stage siRNA player with a small focused pipeline targeting similar delivery and indication profiles.
Emerging players
- Noxxon Pharma: Noxxon is a clinical-stage company developing Spiegelmer-based oligonucleotide therapeutics that intercept disease-related proteins. It is comparable as a small clinical-stage oligonucleotide therapeutics company pursuing gene-expression modulation via RNA-based mechanisms.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
Quark Pharmaceuticals social profiles
Digital presenceQuark Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quark Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles4 records
Quark Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quark Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quark Pharmaceuticals
What does Quark Pharmaceuticals do?
Quark Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of novel RNAi-based therapeutics. The company applies siRNA (small interfering RNA) gene silencing technology to develop innovative drug candidates targeting serious disease indications. As a clinical-stage company, its focus is on advancing therapeutic candidates through preclinical and clinical development rather than commercial product sales.
Is Quark Pharmaceuticals a public or private company?
Quark Pharmaceuticals is a private company. It is classified as venture growth investor backed.
When was Quark Pharmaceuticals founded?
Quark Pharmaceuticals was founded in 1994. It employs 51 to 100 people.
Where is Quark Pharmaceuticals based?
Quark Pharmaceuticals is headquartered in Fremont, United States, in the North America region.
Who are Quark Pharmaceuticals's main competitors?
Broad incumbents on record are Alnylam Pharmaceuticals, Ionis Pharmaceuticals and Arcturus Therapeutics. Direct peers are Arrowhead Pharmaceuticals, Silence Therapeutics, Wave Life Sciences, Dicerna Pharmaceuticals, Sirnaomics and Sylentis (Pharma Mar). Noxxon Pharma is listed as an emerging player.
Does Quark Pharmaceuticals have an API?
No public API is recorded for Quark Pharmaceuticals.
What industry is Quark Pharmaceuticals in?
Quark Pharmaceuticals's product category is RNAi-based Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 2834.